Cargando…

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma

The determination of prognosis for B-Non-Hodgkin's lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells. Both markers are thought to have an effect on prognosis of mature B-cell neoplasms. Fort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmoud, Hanan Mohamed, El-Sakhawy, Yasmin Nabil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269794/ https://www.ncbi.nlm.nih.gov/pubmed/22593817 http://dx.doi.org/10.4081/hr.2011.e26

Ejemplares similares

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

BCL-6 and other genomic alterations in non-Hodgkin's lymphoma (NHL).
por: Butler, M., et al.
Publicado: (1997)

Infrequent BCL10 Mutations in B‐Cell Non‐Hodgkin's Lymphomas
por: Takahashi, Hidenobu, et al.
Publicado: (1999)

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2020)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma
por: Shi, Yaoyao, et al.
Publicado: (2016)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

BCL-1 Gene Rearrangements in Iranian Non-Hodgkin Lymphoma Patients
por: Tohidirad, Manoush, et al.
Publicado: (2016)

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma
por: Dupont, Thibault, et al.
Publicado: (2015)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Expression of c-Myc, Bcl2, Bcl6, and Cyclin D1 in High-Grade B-Cell Lymphoma
por: Ali, Seemal, et al.
Publicado: (2022)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
por: Akpa, Chidimma Agatha, et al.
Publicado: (2019)

Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice
por: Perez-Chacon, Gema, et al.
Publicado: (2019)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

Four genetic lymphoma-specific events (MYC, BCL2, BCL6 and CCND1) identified in a high grade B lymphoma case
por: Ittel, A, et al.
Publicado: (2015)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Targeting the Bcl-2 Family in B Cell Lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Bcl-B: an “unknown” protein of the Bcl-2 family
por: Pervushin, N. V., et al.
Publicado: (2023)

Chronic simian immunodeficiency virus infection is associated with contrasting phenotypes of dysfunctional Bcl6(+) germinal center B cells or Bcl6(−)Bcl2(+) non‐germinal center B cells
por: Onabajo, Olusegun O., et al.
Publicado: (2018)

The epigenetic regulator CTCF modulates BCL6 in lymphoma
por: Batlle-López, Ana, et al.
Publicado: (2015)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients
por: Ting, Choo-Yuen, et al.
Publicado: (2019)

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Mitobe, Masaki, et al.
Publicado: (2018)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation
por: Yang, Haopeng, et al.
Publicado: (2019)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma
por: Batmanov, Kirill, et al.
Publicado: (2017)

Profiling Immune Escape in Hodgkin’s and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining
por: Péricart, Sarah, et al.
Publicado: (2018)

Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry
por: Abdel-Ghafar, Afaf Abdel-Aziz, et al.
Publicado: (2012)

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2014)

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction
por: Mitobe, Masaki, et al.
Publicado: (2021)

A purine scaffold Hsp90 inhibitor destabilizes Bcl6 and has specific anti-tumor activity in Bcl6 dependent B-cell lymphomas
por: Cerchietti, Leandro C, et al.
Publicado: (2009)

STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)
por: Ritz, Olga, et al.
Publicado: (2013)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma
por: Ghanem, M A, et al.
Publicado: (2001)

Correction: MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Publicado: (2014)

Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2018)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

Redefining the high‐grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report
por: Rodríguez‐Pinilla, Socorro María, et al.
Publicado: (2021)

Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis
por: Zeremski, Vanja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rggcvlj1jvqclft0m4chs946ds